Back to Search
Start Over
Early cancer cachexia phenotype predicts survival of advanced urothelial cancer patients treated with pembrolizumab
- Source :
- Asia-Pacific journal of clinical oncologyREFERENCES. 18(4)
- Publication Year :
- 2021
-
Abstract
- AIM We aimed to explore the association between cancer cachexia phenotypes in the early phase of treatment induction and the prognosis of advanced urothelial cancer (aUC) patients receiving pembrolizumab. METHODS This retrospective study included 31 aUC patients treated with pembrolizumab as a second- or later-line therapy. Patients were categorized into three early cancer cachexia phenotypes by changes in skeletal muscle and total adipose indices calculated using computed tomography images taken immediately before and within 3 months after the initiation of pembrolizumab: No Wasting (NW, 11 patients), Fat-Only Wasting (FW, 13), and Muscle and Fat Wasting (MFW, seven). Its association with objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) were evaluated. RESULTS The median follow-up period was 5.7 months. The median number of cycles of pembrolizumab was five. The ORR in NW/FW/MFW was 86%/38%/0%, respectively (p = 0.001). The PFS and OS rates were the best in NW, followed in order by FW and MFW (PFS, 69%/45%/0% at 12 months, p = 0.008; OS, 100%/65%/0% at 12 months, p
- Subjects :
- medicine.medical_specialty
Carcinoma, Transitional Cell
Cachexia
business.industry
Hazard ratio
Retrospective cohort study
General Medicine
Pembrolizumab
medicine.disease
Antibodies, Monoclonal, Humanized
Phenotype
Gastroenterology
Oncology
Internal medicine
Sarcopenia
medicine
Carcinoma
Humans
medicine.symptom
business
Wasting
Retrospective Studies
Subjects
Details
- ISSN :
- 17437563
- Volume :
- 18
- Issue :
- 4
- Database :
- OpenAIRE
- Journal :
- Asia-Pacific journal of clinical oncologyREFERENCES
- Accession number :
- edsair.doi.dedup.....e05e411cb6eab5a1b5d79d3a9cfe37f0